Edition:
United States

Celsion Corp (CLSN.O)

CLSN.O on Consolidated Issue listed on NASDAQ Capital Market

2.14USD
20 Nov 2017
Change (% chg)

$0.00 (+0.00%)
Prev Close
$2.14
Open
--
Day's High
--
Day's Low
--
Volume
906,205
Avg. Vol
2,644,004
52-wk High
$12.50
52-wk Low
$1.24

Chart for

About

Celsion Corporation is an oncology drug development company. The Company's product candidate is ThermoDox, a heat-activated liposomal encapsulation of doxorubicin, which is in Phase III clinical trial for treatment of primary liver cancer (the OPTIMA Study) and a Phase II clinical trial for treatment of recurrent chest wall... (more)

Overall

Beta: 1.09
Market Cap(Mil.): $34.37
Shares Outstanding(Mil.): 16.06
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 200.64 15.49
EPS (TTM): -- -- --
ROI: -- -10.01 11.95
ROE: -- -35.77 15.94

BRIEF-Celsion reports Q3 loss of $0.70/shr

* Celsion Corporation reports third quarter 2017 financial results and provides business update

Nov 14 2017

BRIEF-Celsion files immunotherapy clinical protocol for the evaluation of Gen-1

* Celsion files immunotherapy clinical protocol for the evaluation of Gen-1 to treat newly diagnosed ovarian cancer

Nov 13 2017

BRIEF-CELSION ANNOUNCES PRICING OF COMMON STOCK OFFERING

* CELSION CORPORATION ANNOUNCES PRICING OF UNDERWRITTEN OFFERING OF COMMON STOCK AND WARRANTS TO PURCHASE COMMON STOCK

Oct 27 2017

BRIEF-Celsion provides update on Thermodox in liver cancer study

* Celsion provides update on Thermodox® in the Phase III Optima study of primary liver cancer

Sep 27 2017

BRIEF-Celsion Corp Q2 loss per share $0.79

* Celsion corporation reports second quarter 2017 financial results and provides business update

Aug 15 2017

BRIEF-Celsion Corp says DMC completes mid-study review of phase III thermodox optima study

* Data monitoring committee completes mid-study review of Celsion's phase III thermodox optima study in primary liver cancer

Aug 07 2017

BRIEF-Celsion Corporation to delist from Tel Aviv stock exchange

* Celsion Corporation to delist from Tel Aviv stock exchange Source text for Eikon: Further company coverage:

Aug 04 2017

BRIEF-Celsion Corp announces data from ovation study

* Celsion corp - ‍announces latest translational data from ovation study in newly diagnosed advanced ovarian cancer patients​ Source text for Eikon: Further company coverage:

Aug 02 2017

BRIEF-Celsion Corp says Anson Funds Management LP reported 9.6 pct passive stake in Co as of July 6 - SEC filing

* Anson Funds Management LP reports 9.6 percent passive stake in Celsion Corp as of July 6 - SEC filing Source text: (http://bit.ly/2uBZEHu) Further company coverage:

Jul 17 2017

BRIEF-Intracoastal Capital reports 8.3 pct passive stake in Celsion

* Intracoastal Capital Llc reports 8.3 percent passive stake in Celsion Corp as of July 6 - SEC filing Source: (http://bit.ly/2vlTnMo) Further company coverage:

Jul 14 2017

Earnings vs. Estimates